Mepsevii® (Vestronidase Alfa-vjbk) - CAM 964HB

Background

Mepsevii (vestronidase alfa-vjbk) is a recombinant human beta-glucuronidase enzyme replacement therapy indicated for the treatment of pediatric and adult patients with Mucopolysaccharidosis VII (MPS VII, Sly syndrome).

Policy

Initial Authorization Criteria

Mepsevii may be considered medically necessary when all of the following criteria are met:

1. Diagnosis of Mucopolysaccharidosis VII (MPS VII)

2. Diagnosis is confirmed by one of the following:

  • Enzyme Assay Deficiency of beta-glucuronidase enzyme activity demonstrated by enzymatic assay
  • Genetic Testing: Molecular genetic testing confirming pathogenic mutation(s) in the GUSB (beta-glucuronidase) gene

3. Prescribed by or in consultation with a physician experienced in the management of lysosomal storage disorders, inherited metabolic disorders, or MPS VII

Authorization Duration: 12 months

Reauthorization Criteria

Mepsevii may be reauthorized when all of the following criteria are met:

1. Documentation of positive clinical response or disease stabilization compared with pretreatment baseline, demonstrated by one or more of the following:

  • Reduction in urinary glycosaminoglycan (uGAG) levels
  • Improvement or stabilization of pulmonary function
  • Improvement or stabilization of endurance, mobility, or ambulation
  • Improvement in walking ability (e.g., 6-minute walk test)
  • Improvement or stabilization of joint mobility/range of motion
  • Improvement in activities of daily living
  • Reduction in hepatosplenomegaly
  • Improvement or stabilization of growth parameters in pediatric patients
  • Physician documentation of meaningful clinical benefit

2. Continued treatment is prescribed by or in consultation with a physician experienced in lysosomal storage disorders, inherited metabolic disorders, or MPS VII

Authorization Duration: 12 months

References

  1. Mepsevii® (vestronidase alfa-vjbk) Prescribing Information. Ultragenyx Pharmaceutical Inc. Current prescribing information.
  2. U.S. Food and Drug Administration (FDA). Mepsevii (vestronidase alfa-vjbk) Biologics License Approval. November 2017.
  3. Harmatz P, Whitley CB, Wang RY, et al. A Novel Beta-Glucuronidase Enzyme Replacement Therapy for Mucopolysaccharidosis VII. Molecular Genetics and Metabolism. 2017;122(1-2):63-69.
  4. Montaño AM, Lock-Hock N, Steiner RD, et al. Clinical Course of Sly Syndrome (MPS VII). Journal of Medical Genetics. 2016;53(6):403-418.
  5. GeneReviews®. Mucopolysaccharidosis Type VII.
  6. National Organization for Rare Disorders (NORD). Mucopolysaccharidosis Type VII (Sly Syndrome).
  7. Giugliani R, Federhen A, Muñoz Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief Review and Guidelines for Treatment. Genetics and Molecular Biology. 2010;33(4):589-604.
  8. Orphanet. Mucopolysaccharidosis Type VII.

Coding Section

Code

Number

Description

ICD-10

E76.29

MPS VII (Sly syndrome)

HCPCS

J3397

Injection, vestronidase alfa-vjbk

CPT

96365

Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

 

96366

Each additional hour (List separately in addition to code for primary procedure).

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2026 Forward

10/01/2026

New Policy

Complementary Content
${loading}